Zhongsheng Pharmaceutical announced that an innovative drug developed independently by Guangdong Zhongsheng Ruichuang Biotechnology Co., Ltd., the holding subsidiary of the company, was accepted by the NMPA for the clinical trial registration application for the drug “treatment of influenza A with a high risk of complications”. The application number is CYHB2601667; it plans to conduct a phase III clinical study to enroll youth and adult influenza A participants aged 12 and above.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.